CoChat
Sign Up
Cited by 584

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Barrier Capacity of Human Placenta for Nanosized Materials

Wick, Peter, Malek, Antoine, Manser, Pius, Meili, Danielle, Maeder-Althaus, Xenia, Diener, Liliane, Diener, Pierre-Andre, Zisch, Andreas, Krug, Harald F., von Mandach, Ursula·2010·Environmental Health Perspectives
DOI 10.1289/ehp.0901200PMC PMC2854775
Open this paper in CoChat — free account

Abstract

Background: Humans have been exposed to fine and ultrafine particles throughout their history. Since the Industrial Revolution, sources, doses, and types of nanoparticles have changed dramatically. In the last decade, the rapidly developing field of nanotechnology has led to an increase of engineered nanoparticles with novel physical and chemical properties. Regardless of whether this exposure is unintended or not, a careful assessment of possible adverse effects is needed. A large number of projects have been carried out to assess the consequences of combustion-derived or engineered nanoparticle exposure on human health. In recent years there has been a growing concern about the possible health influence of exposure to air pollutants during pregnancy, hence an implicit concern about potential risk for nanoparticle exposure in utero. Previous work has not addressed the question of whether nanoparticles may cross the placenta. Objective: In this study we investigated whether particles can cross the placental barrier and affect the fetus. Methods: We used the ex vivo human placental perfusion model to investigate whether nanoparticles can cross this barrier and whether this process is size dependent. Fluorescently labeled polystyrene beads with diameters of 50, 80, 240, and 500 nm were chosen as model particles. Results: We showed that fluorescent polystyrene particles with diameter up to 240 nm were taken up by the placenta and were able to cross the placental barrier without affecting the viability of the placental explant. Conclusions: The findings suggest that nanomaterials have the potential for transplacental transfer and underscore the need for further nanotoxicologic studies on this important organ system.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1289/ehp.0901200

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 SEM and size distribution of PS beads. (A–D) SEM micrographs depict the beads with diameters of 50 nm (A), 80 nm (B), 240 nm (C), and 500 nm (D). (E) The size distributions of all applied particles were measured in the perfusion medium, presented as a size–density plot.
Figure 1 SEM and size distribution of PS beads. (A–D) SEM micrographs depict the beads with diameters of 50 nm (A), 80 nm (B), 240 nm (C), and 500 nm (D). (E) The size distributions of all applied particles were measured in the perfusion medium, presented as a size–density plot.CC0 · PubMed Central
Figure 2 Perfusion profiles of PS beads and 14C-antipyrine. After the prephase, PS beads of different sizes were added to the maternal circuit to a final concentration of 25 μg/mL and the amount of 14C-antipyrine and PS beads in both maternal circuits (M, solid symbols) and fetal circuits (F, open symbols) were measured after the indicated time points. (A) In the fetal circuit, significantly increased levels of 50-, 80-, and 240-nm PS beads were measured after only a few minutes of perfusion, whereas the 500-nm beads were retained in the placental tissue and maternal circuit. A second addition of particles after 180 min (arrow) did not further increase the amount of beads in the fetal circuit. (B) The perfusion profiles of 14C-antipyrine were not affected by the presence of beads and maintained equilibrium until the end of the perfusion assay. Data represent mean ± SE of at least four independent experiments.
Figure 2 Perfusion profiles of PS beads and 14C-antipyrine. After the prephase, PS beads of different sizes were added to the maternal circuit to a final concentration of 25 μg/mL and the amount of 14C-antipyrine and PS beads in both maternal circuits (M, solid symbols) and fetal circuits (F, open symbols) were measured after the indicated time points. (A) In the fetal circuit, significantly increased levels of 50-, 80-, and 240-nm PS beads were measured after only a few minutes of perfusion, whereas the 500-nm beads were retained in the placental tissue and maternal circuit. A second addition of particles after 180 min (arrow) did not further increase the amount of beads in the fetal circuit. (B) The perfusion profiles of 14C-antipyrine were not affected by the presence of beads and maintained equilibrium until the end of the perfusion assay. Data represent mean ± SE of at least four independent experiments.CC0 · PubMed Central
Figure 3 Size-dependent barrier capacity of the placental tissue. The ratios between fetal (F) and maternal (M) concentrations of 14C-antipyrine (open bars) and PS beads (blue bars) were calculated after 180 min of perfusion. The 14C-antipyrine values remain unchanged, whereas the perfusion rate of the beads showed size dependence. Data represent mean ± SE of at least four independent experiments. *p < 0.05 compared with 240-nm ratio value; **p < 0.05 compared with 80-nm ratio value; #p < 0.05 compared with 50-nm ratio value.
Figure 3 Size-dependent barrier capacity of the placental tissue. The ratios between fetal (F) and maternal (M) concentrations of 14C-antipyrine (open bars) and PS beads (blue bars) were calculated after 180 min of perfusion. The 14C-antipyrine values remain unchanged, whereas the perfusion rate of the beads showed size dependence. Data represent mean ± SE of at least four independent experiments. *p < 0.05 compared with 240-nm ratio value; **p < 0.05 compared with 80-nm ratio value; #p < 0.05 compared with 50-nm ratio value.CC0 · PubMed Central
Figure 4 Viability and functionality of the placenta were not affected after perfusion with PS beads. (A) Glucose consumption and lactate production in the perfused tissue. (B) Human choriongonadotropin and leptin hormone net production during perfusion [NP divided by initial tissue content (T0)]. Data represent mean ± SE of at least four independent experiments.
Figure 4 Viability and functionality of the placenta were not affected after perfusion with PS beads. (A) Glucose consumption and lactate production in the perfused tissue. (B) Human choriongonadotropin and leptin hormone net production during perfusion [NP divided by initial tissue content (T0)]. Data represent mean ± SE of at least four independent experiments.CC0 · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Research works printed but not linked: 31

  1. Alfaro-Moreno, 2007, Particulate matter in the environment: pulmonary and cardiovascular effects, Curr Opin Pulm Med, 13, 98, 10.1097/MCP.0b013e328013f47e · DOI
  2. Challier, 1985, Criteria for evaluating perfusion experiments and presentation of results, Contrib Gynecol Obstet, 13, 32, 10.1159/000410667 · DOI
  3. Conner, 2003, Regulated portals of entry into the cell, Nature, 422, 37, 10.1038/nature01451 · DOI
  4. Enders, 1999, Comparative placental structure, Adv Drug Deliv Rev, 38, 3, 10.1016/S0169-409X(99)00003-4 · DOI
  5. Ganapathy, 2000, Placental transporters relevant to drug distribution across the maternal-fetal interface, J Pharmacol Exp Ther, 294, 413, 10.1016/S0022-3565(24)39087-1 · DOI
  6. Geiser, 2005, Ultrafine particles cross cellular membranes by nonphagocytic mechanisms in lungs and in cultured cells, Environ Health Perspect, 113, 1555, 10.1289/ehp.8006 · DOI
  7. Hillaireau, 2009, Nanocarrier’s entry into the cell: relevance to drug delivery, Cell Mol Life Sci, 66, 2873, 10.1007/s00018-009-0053-z · DOI
  8. Kanno, 2007, A murine scavenger receptor MARCO recognizes polystyrene nanoparticles, Toxicol Sci, 97, 398, 10.1093/toxsci/kfm050 · DOI
  9. Kertschanska, 1997, Pressure dependence of so-called transtrophoblastic channels during fetal perfusion of human placental villi, Microsc Res Tech, 38, 52, 10.1002/(SICI)1097-0029(19970701/15)38:1/2<52::AID-JEMT7>3.0.CO;2-W · DOI
  10. Kreyling, 2004, Dosimetry and toxicology of ultrafine particles, J Aerosol Med, 17, 140, 10.1089/0894268041457147 · DOI
  11. Lacasana, 2005, Exposure to ambient air pollution and prenatal and early childhood health effects, Eur J Epidemiol, 20, 183, 10.1007/s10654-004-3005-9 · DOI
  12. Latzin, 2008, Air pollution during pregnancy and lung function in newborns: a birth cohort study, Eur Respir J, 33, 594, 10.1183/09031936.00084008 · DOI
  13. Malek, 2009, The impact of cocaine and heroin on the placental transfer of methadone, Reprod Biol Endocrinol, 7, 61, 10.1186/1477-7827-7-61 · DOI
  14. Malek, 1994, Maternal-fetal transport of immunoglobulin G and its subclasses during the third trimester of human pregnancy, Am J Reprod Immunol, 32, 8, 10.1111/j.1600-0897.1994.tb00873.x · DOI · Paper page
  15. Malek, 2000, Production of protein hormones by cultured trophoblast cells isolated from term and early placentae, Am J Reprod Immunol, 43, 278, 10.1111/j.8755-8920.2000.430506.x · DOI
  16. Malek, 2001, Capacity for hormone production of cultured trophoblast cells obtained from placentae at term and in early pregnancy, J Assist Reprod Genet, 18, 299, 10.1023/A:1016674503298 · DOI
  17. Myllynen, 2008, Kinetics of gold nanoparticles in the human placenta, Reprod Toxicol, 26, 130, 10.1016/j.reprotox.2008.06.008 · DOI · Paper page
  18. Nemmar, 2007, Cardiovascular and lung inflammatory effects induced by systemically administered diesel exhaust particles in rats, Am J Physiol Lung Cell Mol Physiol, 292, L664, 10.1152/ajplung.00240.2006 · DOI
  19. Nemmar, 2005, Evaluation of particle translocation across the alveolo-capillary barrier in isolated perfused rabbit lung model, Toxicology, 208, 105, 10.1016/j.tox.2004.11.012 · DOI
  20. Nemmar, 2008, The acute proinflammatory and prothrombotic effects of pulmonary exposure to rutile TiO2 nanorods in rats, Exp Biol Med (Maywood), 233, 610, 10.3181/0706-RM-165 · DOI
  21. Panigel, 1967, Radioangiographic study of circulation in the villi and intervillous space of isolated human placental cotyledon kept viable by perfusion [Letter] [in French], J Physiol (Paris), 59, 277
  22. Pietzonka, 2002, Transfer of lipophilic markers from PLGA and polystyrene nanoparticles to caco-2 monolayers mimics particle uptake, Pharm Res, 19, 595, 10.1023/A:1015393710253 · DOI
  23. Reddy, 2007, Exploiting lymphatic transport and complement activation in nanoparticle vaccines, Nat Biotechnol, 25, 1159, 10.1038/nbt1332 · DOI
  24. Rothen-Rutishauser, 2006, Interaction of fine particles and nanoparticles with red blood cells visualized with advanced microscopic techniques, Environ Sci Technol, 40, 4353, 10.1021/es0522635 · DOI
  25. Rudin, 2003, Molecular imaging in drug discovery and development, Nat Rev Drug Discov, 2, 123, 10.1038/nrd1007 · DOI
  26. Schneider, 1972, Transfer across the perfused human placenta of antipyrine, sodium and leucine, Am J Obstet Gynecol, 114, 822, 10.1016/0002-9378(72)90909-X · DOI
  27. Semmler-Behnke, 2007, Uptake of 1.4 nm versus 18 nm gold nanoparticles in secondary target organs is size dependent in control and pregnant rats after intratrecheal or intravenous application, 102
  28. Stoeger, 2006, Instillation of six different ultrafine carbon particles indicates a surface area threshold dose for acute lung inflammation in mice, Environ Health Perspect, 114, 328, 10.1289/ehp.8266 · DOI
  29. Syme, 2004, Drug transfer and metabolism by the human placenta, Clin Pharmacokinet, 43, 487, 10.2165/00003088-200443080-00001 · DOI
  30. Takata, 1997, Ultrastructure of the rodent placental labyrinth: a site of barrier and transport, J Reprod Dev, 43, 13, 10.1262/jrd.43.13 · DOI
  31. Thiesen, 2008, Clinical applications of magnetic nanoparticles for hyperthermia, Int J Hyperthermia, 24, 467, 10.1080/02656730802104757 · DOI · Paper page

Cited by

Sorted by citations

Metadata

Authors
Wick, P., Malek, A., Manser, P., Meili, D., Maeder-Althaus, X., Diener, L., Diener, P.-A., Zisch, A., Krug, H. F., & von Mandach, U.
Venue
Environmental Health Perspectives
Publisher
American Chemical Society (ACS)
Published
2009-11-12
Volume
118
Issue
3
Pages
432-436
ISSN
  • 0091-6765
  • 1552-9924
DOI
10.1289/ehp.0901200
PMC
PMC2854775
Cited by
584
References
1
Language
en
Licence
creativecommons.org/licenses/by/4.0/ (vor, 2969 d)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review